Adverse event rates low in AMD patients who take anti-VEGFs

Patients treated with anti-VEGFs for age-related macular degeneration had a low rate of adverse events that was comparable to the rate in the general population in Singapore, a study found.The retrospective population-based study included 1,182 patients with AMD who received at least one intravitreal anti-VEGF injection between 2008 and 2011. Mean follow-up was 2 years, and mean number of injections was 4.67.